Transfusion Transmitted Cytomegalovirus

References

• Kaariainen L, Klemola E, Paloheimo J. Rise of cytomegalovirus antibodies in an infectious mononucleosis-like syndrome after transfusion. Br Med J 1965; 2: 1270–1272
   Google Scholar
• Bowden R, Sayers M. The risk of transmitting cytomegalovirus infection by fresh frozen plasma. Transfusion 1990; 30: 762–763
   PubMed Web of Science ®Google Scholar
• James D J, Sikotra S, Sivakumaran M, et al. The presence of free infectious cytomegalovirus (CMV) in the plasma of donated CMV-seropositive blood and platelets. Transfus Med 1997; 7: 123–126
   Web of Science ®Google Scholar
• Adler S P, McVoy M M. Cytomegalovirus infections in seropositive patients after transfusion. The effect of red cell storage and volume. Transfusion 1989; 29: 667–671
   Google Scholar
• Preiksaitis J K, Brown L, McKenzie M. The risk of cytomegalovirus infection in seronegative transfusion recipients not receiving exogenous immunosuppression. J Infect Dis 1988; 157: 523–529
   PubMed Web of Science ®Google Scholar
• Soderberg-Naucler C, Fish K N, Nelson J A. Growth of human cytomegalovirus in primary macrophages. Methods 1998; 16: 126–138
   Google Scholar
• Soderberg-Naucler C, Fish K N, Nelson J A. Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors. Cell 1997; 91: 119–126
   PubMed Web of Science ®Google Scholar
• Larsson S, Soderberg-Naucler C, Moller E. Productive cytomegalovirus (CMV) infection exclusively in CD 13-positive peripheral blood mononuclear cells from CMV-infected individuals: implications for prevention of CMV transmission. Transplantation 1998; 65: 411–415
   Google Scholar
• Soderberg C, Giugni T D, Zaia J A, Larsson S, Wahlberg J M, Moller E. CD 13 (human aminopeptidase N) mediates human cytomegalovirus infection. J Virol 1993; 67: 6576–6585
   PubMedGoogle Scholar
• Giugni T D, Soderberg C, Ham D J, et al. Neutralization of human cytomegalovirus by human CD13-specific antibodies. J Infect Dis 1996; 173: 1062–1071
   Google Scholar
• Tegtmeier G E. Posttransfusion cytomegalovirus infections. Arch Pathol Lab Med 1989; 113: 236–245
   PubMed Web of Science ®Google Scholar
• Kane R C, Rousseau W R, Noble G R, et al. Cytomegalovirus infection in a volunteer blood donor population. Infect Immun 1975; 11: 719–723
   PubMed Web of Science ®Google Scholar
• Wingard J R, Chen D Y, Burns W H, et al. Cytomegalovirus infection after autologous bone marrow transplantation with comparison to infection after allogeneic bone marrow transplantation. Blood 1988; 71: 1432–1437
   PubMed Web of Science ®Google Scholar
• Meyers J D, Flournoy N, Thomas E D. Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis 1986; 153: 478–488
   PubMed Web of Science ®Google Scholar
• Bowden R, Sayers M, Flournoy N, et al. Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. N Engl J Med 1986; 314: 1006–1010
   PubMed Web of Science ®Google Scholar
• Mackinnon S, Burnett A K, Crawford R J, Cameron S, Leask B G, Sommerville R G. Seronegative blood products prevent primary cytomegalovirus infection after bone marrow transplantation. J Clin Pathol 1988; 41: 948–950
   PubMed Web of Science ®Google Scholar
• Preiksaitis J K, Desai S, Vaudry W, et al. Transfusion- and community-acquired cytomegalovirus infection in children with malignant disease: a prospective study. Transfusion 1997; 941–946
   Google Scholar
• Bowden R A, Slichter S J, Sayers M, et al. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood 1995; 86: 3598–3603
   PubMed Web of Science ®Google Scholar
• Schreiber G B, Busch M P, Kleinman S H, Korelitz J J. The risk of transfusion-transmitted viral infections. N Engl J Med 1996; 334: 1685–1690
   PubMed Web of Science ®Google Scholar
• Minutes of the Blood Products Advisory Committee. Department of Health and Human Services, Public Health Service, Food and Drug Administration, Rockville, MD 1997, Friday, September 19
   Google Scholar
• Zbinden R, Decurtins M, Wunderli W. Latex agglutination test for cytomegalovirus antibody screening of transplant donors. Important aspects. Diag Microbiol Infect Dis 1992; 15: 407–409
   Google Scholar
• Larsson S, Soderberg-Naucler C, Wang F Z, Moller E. Cytomegalovirus DNA can be detected in peripheral blood mononuclear cells from all seropositive and most seronegative healthy blood donors over time. Transfusion 1998; 38: 271–278
   PubMed Web of Science ®Google Scholar
• Luban N L, Williams A E, MacDonald M G, Mikesell G T, Williams K M, Sacher R A. Low incidence of acquired cytomegalovirus infection in neonates transfused with washed red blood cells. Am J Dis Child 1987; 141: 416–419
   PubMedGoogle Scholar
• Adler S P, Bagget J, McVoy M. Transfusion-associated cytomegalovirus infections in seropositive cardiac surgery patients. Lancet 1985; 2: 743–745
   Google Scholar
• Thompson K S, Plapp F V, Long N D, Heenan T A. CMV infection in heart transplant recipients. Transfusion 1992; S249
   Google Scholar
• Ledent E, Berlin G. Inadequate white cell reduction by bedside filtration of red cell concentrates. Transfusion 1994; 34: 765–768
   Google Scholar
• Ledent E, Berlin G. Factors influencing white cell removal from red cell concentrates by filtration. Tranfusion 1996; 36: 714–718
   Google Scholar
• Sirchia G, Rebulla P, Sabbioneda L, Garcea F, Greppi N. Optimal conditions for white cell reduction in red cells by filtration at the patient's bedside. Transfusion 1996; 36: 322–327
   Google Scholar
• Zingsem J, Glaser A, Weisbach V, et al. Evaluation of a platelet apheresis technique for the preparation of leukocyte-reduced platelet concentrates. Vox Sang 1998; 74: 189–192
   PubMed Web of Science ®Google Scholar
• De Witte T, Schattenberg A, Van Dijk B A, et al. Prevention of primary cytomegalovirus infection after allogeneic bone marrow transplantation by using leukocyte-poor random blood products from cytomegalovirus-unscreened blood-bank donors. Transplantation 1990; 50: 964–968
   Web of Science ®Google Scholar
• Bowden R A, Sayers M H, Cays M, Slichter S J. The role of blood product filtration in the prevention of transfusion associated cytomegalovirus (CMV) infection after marrow transplant. Transfusion 1989; 29((Suppl))57S
   Google Scholar
• Sowemimo-Coker S O, Kim A, Tribble E, Brandwein H J, Wenz B, et al. White cell subsets in apheresis and filtered platelet concentrates. Transfusion 1998; 38: 650–657
   Google Scholar
• Smith D M, Lipton K S. Leukocyte reduction for the prevention of transfusion-transmitted cytomegalovirus. Association Bulletin 97–2. American Association of Blood Banks 1997
   Google Scholar
• Landaw E M, Kanter M, Petz L D. Safety of filtered leukocyte-reduced blood products for prevention of transfusion-associated cytomegalovirus infection (letter). Blood 1996; 4910–4911
   Google Scholar
• Zhang L J, Hanff P, Rutherford C, Churchill W H, Crumpacker C S. Detection of human cytomegalovirus DNA, RNA, and antibody in normal donor blood. J Infect Dis 1995; 171: 1002–1006
   PubMed Web of Science ®Google Scholar
• Elfath M D, Luka J, Dumont L J. Persistence of CMV after leukocyte-reduction of blood products. Transfusion 1998; 38: S400
   Google Scholar
• Roback J D, Bray R A, Hillyer C D. Quantitation of CMV-associated leukocyte (WBC) subsets in red blood cell (RBC) units with leukoreduction (LR) and storage. Transfusion 1998; 38: S401
   Google Scholar
• McDonough S H, Giachetti C, Yang Y, Kolk D P, Billyard E, Mimms L. High throughput assay for the simultaneous or separate detection of human immunodeficiency virus (HIV) and hepatitis type C virus (HCV). Infusionsther Transfusionsmed 1998; 25: 164–169
   Google Scholar
• Minutes of the Nucleic Acid Testing for HCV and Other Viruses in Blood Donors Workshop. Department of Health and Human Services, Public Health Service, Food and Drug Administration, Rock-ville, MD 1998, Wednesday, September 16
   Google Scholar
• Corash L. Inactivation of viruses, bacteria, protozoa, and leukocytes in platelet concentrates: current research perspectives. Trans Med Rev 1999; 13: 18–30
   PubMed Web of Science ®Google Scholar
• Grass J A, Hei D J, Metchette K, et al. Inactivation of leukocytes in platelet concentrates by photochemical treatment with psoralen plus UVA. Blood 1998; 91: 2180–2188
   Google Scholar
• Wagner S J, Skripchenko A, Robinette D, Mallory D A, Cincotta L. Preservation of red cell properties after virucidal phototreatment with dimethylmethylene blue. Transfusion 1998; 38: 729–737
   PubMed Web of Science ®Google Scholar
• Wagner S J, Skripchenko A, Robinette D, Foley J W, Cincotta L. Factors affecting virus photoinactivation by a series of phenothiazine dyes. Photochem Photobiol 1998; 67: 343–349
   PubMed Web of Science ®Google Scholar
• Cook D N. Progress in the inactivation of pathogens in platelet concentrates and packed red blood cells. Blood Safety & Screening Proc McLean, VA 1999, February 23–24
   Google Scholar
• Ackerman S K. Inactivation of enveloped and nonenveloped viruses in red blood cell concentrates. Blood Safety & Screening. Proc McLean, VA 1999, February 23–24
   Google Scholar
• Margolis-Nunno H, Ben-Hur E, Gottlieb P, Robinson R, Oetjen J, Horowitz B. Inactivation by phthalocyanine photosensitization of multiple forms of human immunodeficiency virus in red cell concentrates. Transfusion 1996; 36: 743–750
   PubMed Web of Science ®Google Scholar